Shots:
- ImmunityBio announced positive results from two clinical studies evaluating ANKTIVA (nogapendekin alfa inbakicept) in combination with checkpoint inhibitors (CPI) in non-small cell lung cancer (NSCLC), demonstrating statistically significant immune restoration across 151 pts
- In 1L NSCLC, the randomized QUILT-2.023 study showed a significant and sustained increase in absolute lymphocyte count (ALC) with ANKTIVA + CPI vs CPI alone (p=0.0065), establishing ANKTIVA’s role as a lymphocyte-stimulating agent
- In 2L+ NSCLC, the single-arm QUILT-3.055 study showed restoration or maintenance of ALC ≥1.0 ×10³ cells/µL in 77% of pts, with responders achieving longer OS vs non-responders (median OS: 16.2 vs 11.8 mos.; HR=0.52; p=0.0369) and pts achieving higher immune competence (ALC ≥1.2 ×10³ cells/µL) showed additional survival benefit, with median OS of 21.1mos.; a P-III confirmatory study (ResQ201A) is ongoing
Ref: ImmunityBio | Image: ImmunityBio | Press Release
Related News: ImmunityBio Reveals P-II (QUILT-3.055) Trial Findings of Anktiva in CPI-Resistant NSCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
